Business Description
Viking Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92686J1060
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 856.6 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -22.2 | |||||
3-Year EPS without NRI Growth Rate | -18.9 | |||||
3-Year FCF Growth Rate | -37.4 | |||||
3-Year Book Growth Rate | 1.4 | |||||
Future 3-5Y EPS without NRI Growth Rate | -22.67 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 47.34 | |||||
9-Day RSI | 50.98 | |||||
14-Day RSI | 51.99 | |||||
6-1 Month Momentum % | -7.01 | |||||
12-1 Month Momentum % | 460.12 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 37.69 | |||||
Quick Ratio | 37.69 | |||||
Cash Ratio | 37.55 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11 | |||||
Shareholder Yield % | -4.49 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -16.36 | |||||
ROA % | -15.78 | |||||
ROIC % | -7923.04 | |||||
ROC (Joel Greenblatt) % | -11076.49 | |||||
ROCE % | -21.04 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 7.92 | |||||
Price-to-Tangible-Book | 7.92 | |||||
EV-to-EBIT | -50.93 | |||||
EV-to-Forward-EBIT | -42.84 | |||||
EV-to-EBITDA | -51.05 | |||||
EV-to-Forward-EBITDA | -42.84 | |||||
EV-to-FCF | -88.25 | |||||
Price-to-Projected-FCF | 21.71 | |||||
Price-to-Net-Current-Asset-Value | 7.93 | |||||
Price-to-Net-Cash | 7.95 | |||||
Earnings Yield (Greenblatt) % | -1.96 | |||||
FCF Yield % | -0.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Viking Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.87 | ||
Beta | 1.09 | ||
Volatility % | 218.96 | ||
14-Day RSI | 51.99 | ||
14-Day ATR (€) | 2.443264 | ||
20-Day SMA (€) | 58.159 | ||
12-1 Month Momentum % | 460.12 | ||
52-Week Range (€) | 8.624 - 91.5 | ||
Shares Outstanding (Mil) | 110.8 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Viking Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Viking Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Viking Therapeutics Inc Frequently Asked Questions
What is Viking Therapeutics Inc(FRA:1VT)'s stock price today?
When is next earnings date of Viking Therapeutics Inc(FRA:1VT)?
Does Viking Therapeutics Inc(FRA:1VT) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |